Adam Mostafa

Cantor Fitzgerald & Co. is the investment bank and brokerage subsidiary of CFS CF & Co. I Holdings LP, which is owned by Cantor Fitzgerald LP in the US. The firm was founded by Bernie Gerald Cantor and John Fitzgerald in 1945. Headquartered in New York City, Cantor Fitzgerald offers clients a global, multi-asset prime brokerage platform with a focus on the quality middle market.

AQR Capital Management LLC (AQR) is a SEC-registered investment advisor and hedge fund manager headquartered in Greenwich, Connecticut. They are a wholly-owned subsidiary of AQR Capital Management Holdings LLC and their ultimate parent is AQR Capital Management Group LP. The firm was founded by Clifford Asness, David Kabiller, and John Liew in 1998. AQR provides investment management services to institutional clients through managed accounts. Their investors may include investment companies, pooled investment vehicles, pension and profit sharing plans, charitable organizations, state or municipal government entities, other investment advisers, insurance companies, sovereign wealth funds and foreign official institutions, corporations or other businesses entities.

Abpro Corp. operates as a biotechnology company which develops antibody therapeutics for severe and life threatening diseases. It focusses on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. The company was founded by Ian Chan and Eugene Y. Chan in 2007 and is headquartered in Woburn, MA.

Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA.

Precision Biologics, Inc. develops therapeutic and diagnostic products for the early detection and treatment of cancer. Its antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. The company was founded in February 2012 and is headquartered in Dallas, TX.

X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA.